Latest news
Debiopharm Licenses SunRock Biopharma’s anti-HER3/HER2 Antibody to Explore the Full Potential of Bispecific ADC Debio 2512
Debiopharm Joins The Working Group Of The Naipo Initiative: Transforming Cancer Care With Artificial Intelligence
Debiopharm’S Pamorelin® Receives Swiss Approval for subcutaneous Administration, Enhancing Treatment Flexibility for Prostate Cancer Patients
Debiopharm Pushes The Boundaries Of Innovation In Antibiotic Development Against Gonorrhea With First-in-human Debio 1453 Trial
Released by Repare Therapeutics: Repare Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
10e Challenge Qualité de vie du patient : cinq projets innovants récompensés, cap vers la finale !
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent…
Debiopharm’s ADC Research Gains Momentum with Launch of First-In-Human Trial Assessing Debio 1562m in Acute Myeloid Leukemia Patients
Debiopharm And Alkyon Therapeutics Announce Research Collaboration To Advance The Next Generation Of Radioligand Therapies
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.